down arrow

Quest PharmaTech, Inc.

  • Market Cap: N/A
  • Industry: Miscellaneous
  • ISIN: CA74836M1068
CAD
0.04
0.00 (0.00%)

Dec 04

TSX

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

0.020.06
Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

CAD 7 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.04

stock-summary
Return on Equity

-4.70%

stock-summary
Price to Book

0.31

Revenue and Profits:
Net Sales:
(Quarterly Results - Apr 2025)
Net Profit:
1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
-12.5%
0%
-12.5%
1 Year
16.67%
0%
16.67%
2 Years
-36.36%
0%
-36.36%
3 Years
-46.15%
0%
-46.15%
4 Years
-61.11%
0%
-61.11%
5 Years
-79.41%
0%
-79.41%

Quest PharmaTech, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
13.78%
EBIT to Interest (avg)
-0.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.04
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
33.29%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.27
EV to EBIT
-6.83
EV to EBITDA
-6.83
EV to Capital Employed
0.30
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.49%
ROE (Latest)
-4.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 177.78% vs -800.00% in Apr 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.10",
          "val2": "-0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.70",
          "val2": "-0.10",
          "chgp": "800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.70",
          "val2": "-0.90",
          "chgp": "177.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jan'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jan 2025 is 0.00% vs 0.00% in Jan 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jan 2025 is 40.00% vs 58.90% in Jan 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jan'25",
        "Jan'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.80",
          "val2": "-1.30",
          "chgp": "38.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-1.30",
          "chgp": "61.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "-3.00",
          "chgp": "40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Apr'25 - YoYstock-summary
Apr'25
Apr'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.10
-0.10
Interest
0.00
0.00
Exceptional Items
0.70
-0.10
800.00%
Consolidate Net Profit
0.70
-0.90
177.78%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Apr 2025 is 177.78% vs -800.00% in Apr 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jan'25stock-summary
Jan'25
Jan'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.80
-1.30
38.46%
Interest
0.00
0.00
Exceptional Items
-0.50
-1.30
61.54%
Consolidate Net Profit
-1.80
-3.00
40.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Jan 2025 is 0.00% vs 0.00% in Jan 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jan 2025 is 40.00% vs 58.90% in Jan 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Quest PharmaTech, Inc. stock-summary
stock-summary
Quest PharmaTech, Inc.
Miscellaneous
Quest PharmaTech Inc. is a Canada-based pharmaceutical company. The Company, through its subsidiary, OncoQuest Inc., is developing immunotherapies for cancer treatment. It operates through two segments: biopharmaceutical/pharmaceutical products and consumer/cosmetic products. OncoQuest's technology platform includes a panel of tumor antigen specific monoclonal immunoglobulins, including CA125, MUC1, PSA, and Her2/neu, and the application of combinatorial immunotherapy. OncoQuest's lead product, oregovomab, is undergoing a Phase IIb clinical trial involving approximately 80 ovarian cancer patients in Italy and the United States. OncoQuest's pipeline of product candidates consists of four other monoclonal antibodies targeting certain tumor antigens that are presented in a range of cancers, including such cancers as breast, lung, pancreas, stomach and prostate. It also markets consumer health products around the world, including Bellus Skin serum, an anti-wrinkle skin care product.
Company Coordinates stock-summary
Company Details
8123 Roper Rd NW , EDMONTON AB : T6E 6S4
stock-summary
Tel: 1 780 4481400
stock-summary
http://www.questpharmatech.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."